THE PROBLEMS OF THE SAFETY OF THERAPY WITH TUMOR NECROSIS FACTOR-а INHIBITORS

Современная ревматология

关键词: rheumatoid arthritis;    adalimumab;    infliximab;    etanercept;    treatment safety;    adverse reactions;   

DOI  :  10.14412/1996-7012-2009-555

来源: DOAJ

【 摘 要 】

Due to the fact that tumor necrosis factor-а (TNF-а) inhibitors are in wide use, the problem of the safety of therapy with drugs of this group is pressing. The review discusses the data of randomized and observational clinical trials of three drugs of this group (adalimumab, infliximab, and etanercept) whether they can cause serious adverse reactions (SAR). The analysis leads to the conclusion that 10 years' experience in using TNF-а inhibitors generally suggests their satisfactory safety profile. Anti-TNF-а therapy is unassociated with the increased risk of fatal outcomes, at the same time one should be alert to tuberculosis, serious bacterial infections, and lymphoma although the frequency of SAR is generally low; the risk for the development of SAR becomes higher as the dose of TNF-а inhibitors is increased and it does not with longer survival. The currently available preventive methods and physicians' alertness to SAR help prevent their development.

【 授权许可】

Unknown